LSA
NTLA icon

Leonteq Securities AG’s Intellia Therapeutics NTLA Stock Holding History

Leonteq Securities AG’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$55.6K Sell
3,289
-5,377
-62% -$75.3K ﹤0.01% 785
2026
Q1 		$111K Sell
8,666
-48,124
-85% -$613K ﹤0.01% 706
2025
Q4 		$511K Buy
56,790
+55,900
+6,281% +$770K 0.02% 455
2025
Q3 		$15.4K Sell
890
-4,008
-82% -$49.4K ﹤0.01% 1069
2025
Q2 		$45.9K Sell
4,898
-4,458
-48% -$36.6K ﹤0.01% 863
2025
Q1 		$66.4K Buy
9,356
+9,265
+10,181% +$93.6K ﹤0.01% 792
2024
Q4 		$1.06K Buy
91
+12
+15% +$187 ﹤0.01% 1186
2024
Q3 		$1.62K Sell
79
-155
-66% -$3.57K ﹤0.01% 1107
2024
Q2 		$5.24K Buy
234
+55
+31% +$1.31K ﹤0.01% 1042
2024
Q1 		$4.92K Hold
179
– – ﹤0.01% 1082
2023
Q4 		$5.46K Buy
179
+72
+67% +$2.07K ﹤0.01% 1052
2023
Q3 		$3.38K Sell
107
-130
-55% -$5.04K ﹤0.01% 1104
2023
Q2 		$9.66K Sell
237
-5,782
-96% -$234K ﹤0.01% 1049
2023
Q1 		$224K Buy
6,019
+1,450
+32% +$56.9K 0.01% 499
2022
Q4 		$159K Sell
4,569
-360
-7% -$17.1K 0.01% 586
2022
Q3 		$276K Buy
4,929
+1,493
+43% +$92.6K 0.01% 466
2022
Q2 		$178K Buy
3,436
+2,706
+371% +$137K 0.01% 577
2022
Q1 		$53K Sell
730
-3,274
-82% -$277K ﹤0.01% 850
2021
Q4 		$473K Buy
4,004
+1,636
+69% +$205K 0.02% 469
2021
Q3 		$318K Buy
+2,368
New +$359K 0.01% 506

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Leonteq Securities AG's NTLA Position: Q2 2026 in Review

Leonteq Securities AG reduced its Intellia Therapeutics (NTLA) stake by 62% in Q2 2026, selling an estimated $75.3K and leaving 3,289 shares worth $55.6K. The position accounts for ﹤0.01% of the portfolio, ranked #785.

Leonteq Securities AG first reported a position in NTLA in Q3 2021 and has held it in 20 quarters since. The position peaked at $511K in Q4 2025. 327 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Leonteq Securities AG held 3,289 shares of Intellia Therapeutics worth $55.6K as of Q2 2026.
  • Leonteq Securities AG sold 5,377 Intellia Therapeutics shares in Q2 2026, an estimated $75.3K.
  • Intellia Therapeutics made up ﹤0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #785 holding.
  • Leonteq Securities AG first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Leonteq Securities AG's Intellia Therapeutics position peaked at $511K in Q4 2025.
  • 327 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.